We partner with the media to inform the public of the global human crisis.
Latest News
-
October 3, 2017
FDA Posts Advisory Committee Meeting Notice for RBP-6000 NDA... -
October 2, 2017
Indivior Submits New Drug Application to U.S. FDA for RBP-7000 Risperidone Monthly Depot for Treatment of Schizophrenia... -
September 27, 2017
Indivior Chief Medical Officer Ponni Subbiah, M.D., Provides Testimony Before the Presidential Commission on Combating Drug Addiction and the Opioid Crisis... -
September 25, 2017
Indivior Enters into Settlement with Mylan Pharmaceuticals in Patent Infringement Case... -
September 15, 2017
Indivior Asserts New Patent Against ANDA Filers...
Global Media Contacts
Email: IndiviorMediaContacts@indivior.com
Phone: +1 804-594-0836
UK Media Contacts
Tulchan Communications LLP
85 Fleet Street
London
EC4Y 1AE
Indivior@Tulchangroup.com
Phone: +44 (020) 7353 4200
Upcoming Events
-
11/2/2017
2017 Q3 and Year-to-Date Results Access >
-
November 2nd
Q3 2017 Financial Results >
EMEA, Australasia and China Financial Disclosure Reporting
Disclosure Of Payments, Donations & Joint Working
Media Kit
The Online Press Kit is designed to help media research our company for background information or follow-up stories. Please visit the links below to learn more.
About Indivior PLC – An overview of Indivior, including our worldwide locations and key products
Board of Directors – Biographies of Indivior’s Board
The Indivior PLC Pipeline – Information about the Indivior R&D efforts and progress of medicines in the pipeline